Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials

The Lancet Psychiatry

Volumn 3, Issue 12, 2016, Pages 1138-1146

  McGirr, Alexander ^a   Vöhringer, Paul A ^b,c,d   Ghaemi, S Nassir ^d   Lam, Raymond W ^a   Yatham, Lakshmi N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^c Millennium Institute for Research in Depression and Personality   (Chile)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; MOOD STABILIZER; PLACEBO; NEUROLEPTIC AGENT;

ARTICLE; BIPOLAR DEPRESSION; CLINICAL PRACTICE; COCHRANE LIBRARY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; HYPOMANIA; MANIA; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SYSTEMATIC REVIEW; BIPOLAR DISORDER; DOUBLE BLIND PROCEDURE;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84997218177     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(16)30264-4     Document Type: Article

References (38)

1. 1 WHO. The global burden of disease: 2004 update, 2008, World Health Organization, Geneva.
2. 2 Judd, LL, Schettler, PJ, Solomon, DA, et al. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. J Affect Disord 108 (2008), 49–58.
3. 3 Kupka, RW, Altshuler, LL, Nolen, WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 9 (2007), 531–535.
4. 4 Perlis, RH, Miyahara, S, Marangell, LB, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 55 (2004), 875–881.
5. 5 Yatham, LN, Kennedy, SH, Parikh, SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 15 (2013), 1–44.
6. 6 Viktorin, A, Lichtenstein, P, Thase, ME, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry 171 (2014), 1067–1073.
7. 7 Mauer, S, Alahmari, R, Vohringer, PA, et al. International prescribing patterns for mood illness: the International Mood Network (IMN). J Affect Disord 167 (2014), 136–139.
8. 8 Gijsman, HJ, Geddes, JR, Rendell, JM, Nolen, WA, Goodwin, GM, Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 161 (2004), 1537–1547.
9. 9 Vazquez, GH, Tondo, L, Undurraga, J, Baldessarini, RJ, Overview of antidepressant treatment of bipolar depression. Int J Neuropsychopharmacol 16 (2013), 1673–1685.
10. 10 Sidor, MM, Macqueen, GM, Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 72 (2011), 156–167.
11. 11 Post, RM, Altshuler, LL, Leverich, GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 189 (2006), 124–131.
12. 12 Nemeroff, CB, Evans, DL, Gyulai, L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 158 (2001), 906–912.
13. 13 Sachs, GS, Nierenberg, AA, Calabrese, JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356 (2007), 1711–1722.
14. 14 Pacchiarotti, I, Bond, DJ, Baldessarini, RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 170 (2013), 1249–1262.
15. 15 Himmelhoch, JM, Thase, ME, Mallinger, AG, Houck, P, Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 148 (1991), 910–916.
16. 16 Higgins, JP, Altman, DG, Gotzsche, PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
17. 17 Deeks, JJ, Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 21 (2002), 1575–1600.
18. 18 Montgomery, SA, Asberg, M, A new depression scale designed to be sensitive to change. Br J Psychiatry 134 (1979), 382–389.
19. 19 Hamilton, M, A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960), 56–62.
20. 20 Sachs, GS, Guille, C, McMurrich, SL, A clinical monitoring form for mood disorders. Bipolar Disord 4 (2002), 323–327.
21. 21 Riley, RD, Higgins, JP, Deeks, JJ, Interpretation of random effects meta-analyses. BMJ, 342, 2011, d549.
22. 22 Fergusson, D, Aaron, SD, Guyatt, G, Hebert, P, Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ 325 (2002), 652–654.
23. 23 Borenstein, M, Hedges, L, Higgins, J, Rothstein, H, Introduction to meta-analysis, 2009, Wiley & Sons, West Sussex.
24. 24 Egger, M, Davey Smith, G, Schneider, M, Minder, C, Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
25. 25 Cooper, H, Hedges, L, Valentine, J, The handbook of research synthesis and meta-analysis, 2009, Russell Sage Foundation Publications, New York.
26. 26 Tohen, M, Vieta, E, Calabrese, J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60 (2003), 1079–1088.
27. 27 Shelton, RC, Stahl, SM, Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 65 (2004), 1715–1719.
28. 28 Yatham, LN, Vieta, E, Goodwin, GM, et al. Agomelatine or placebo as adjunctive therapy to a mood stabilizer in bipolar I depression: randomised double-blind placebo controlled trial. Br J Psychiatry 208 (2016), 78–86.
29. 29 Ghaemi SN. Antidepressants in bipolar depression: an update. 168th annual meeting of the American Psychiatric Association; Toronto, ON, Canada; May 16–20, 2015.
30. 30 Rosenthal, R, Meta-analytic procedures for social research, 1993, Sage Publications, Newbury Park, CA.
31. 31 Bridge, JA, Birmaher, B, Iyengar, S, Barbe, RP, Brent, DA, Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 166 (2009), 42–49.
32. 32 Agid, O, Siu, CO, Potkin, SG, et al. Meta-regression analysis of placebo response in antipsychotic trials, 1970–2010. Am J Psychiatry 170 (2013), 1335–1344.
33. 33 Lombardo, I, Sachs, G, Kolluri, S, Kremer, C, Yang, R, Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?. J Clin Psychopharmacol 32 (2012), 470–478.
34. 34 Durgam, S, Earley, W, Lipschitz, A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry 173 (2016), 271–281.
35. 35 Sachs, GS, Lafer, B, Stoll, AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 55 (1994), 391–393.
36. 36 Peet, M, Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 164 (1994), 549–550.
37. 37 Berk, M, Ng, F, Dodd, S, Goldberg, JF, Malhi, GS, Do we need to flick the switch? The need for a broader conceptualization of iatrogenic course aggravation in clinical trials of bipolar disorder. Psychiatry Clin Neurosci 64 (2010), 367–371.
38. 38 Goodwin, GM, Haddad, PM, Ferrier, IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 30 (2016), 495–553.